Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Mar-Apr;22(2A):805-8.

Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix

Han-Seong Kim  1 , Katsuya Shiraki, Sung-Hye Park
Affiliations
  • PMID: 12014654

Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix

Han-Seong Kim et al. Anticancer Res. 2002 Mar-Apr.

Abstract

Background: Survivin is a novel member of the inhibitors of apotosis proteins (IAP). To evaluate the possible role of survivin in tumorigenesis of CIN (cervical intraepithelial neoplasia) and invasive squamous cervical carcinoma of the uterine cervix (SCC), the expression of survivin was studied.

Materials and results: In 41 CIN and SCC tissues, the expression of survivin, Fas-ligand, Fas and bcl-2 was studied by immunohistochemistry. Survivin expression tended to increase along with tumor progression; low-grade squamous intra-epithelial lesions (HSIL, CIN I), 66.7%, high-grade squamous epithelial lesions (HSIL, CIN II and III), 87.5% and SCC, 100% with a statistical significance (p<0.019). Alteration of Fas-ligand, Fas and bcl-2 expression was detected in 12.5%-25% of HSIL and in 7.7%-30.8% of SCC but no abnormal expression was found in LSIL.

Conclusion: Survivin expression seems to be more closely related to the progression of CIN and SCC compared to Fas-ligand, Fas and bcl-2.

PubMed Disclaimer

MeSH terms